Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016
U.S. dermatology and Latin American sales drive 37% product revenue growth FDA 510k clearance for treatment of atopic dermatitis with a unique "no touch" spray gel Cash as of June 30, 2015 of $8.8 million and debt free Conference call begins at 4:30 p.m. EDT today PETALUMA, Calif.
View HTML
Toggle Summary Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call
PETALUMA, Calif. , July 16, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2016, ended June 30, 2015 , will be released after the U.S. markets close on July 30, 2015 .
View HTML
Toggle Summary Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of Atopic Dermatitis
PETALUMA, Calif. , July 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of a new U.S.
View HTML
Toggle Summary Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule
PETALUMA, Calif. , June 18, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) (Nasdaq:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that it received a
View HTML
Toggle Summary Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
Ruthigen /Pulmatrix merger closed on June 15, 2015 , enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015 Sale provides non-dilutive funding to support sales growth of dermatology products via Oculus' direct sales force PETALUMA, Calif.
View HTML
Toggle Summary Oculus Innovative Sciences Reports Financial Results for the Fourth Quarter of Fiscal Year 2015
Total revenue increased 37% to $4 million from $2.9 million in the same period last year; up 25% from the quarter ending December 31, 2014 Cash as of March 31, 2015 of $6.1 million and debt free Upon completion of Ruthigen merger, Oculus will receive an additional $4.5 million from the sale of
View HTML
Toggle Summary Oculus Innovative Sciences Receives FDA Clearance for Novel Atopic Dermatitis Dermatology Product
PETALUMA, Calif. , June 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that it has received a new 510(k)
View HTML
Toggle Summary Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2015 Financial Results and Conference Call
PETALUMA, Calif. , May 28, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal fourth quarter 2015, ended March 31, 2015 , will be released after the U.S. markets close on June 11, 2015 .
View HTML
Toggle Summary Oculus Innovative Sciences Announces Launch of MicrocynAH(R) Farm and Ranch Animal Healthcare Products
Ten North American distributors have added MicrocynAH® animal healthcare products to their product portfolios since launch in February 2015 Antibiotic-free MicrocynAH® helps create an optimal wound healing environment without the use of antibiotics, better enabling farmers and ranchers to support
View HTML